;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss

Headlines

US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss

Published by Global Banking and Finance Review

Posted on May 2, 2025

Featured image for article about Headlines

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its weight-loss drug Wegovy and will take a decision by the fourth quarter, the Danish drugmaker said on Friday.

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.

Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes.

(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)

More from Headlines

Explore more articles in the Headlines category

German parliament suffers suspected cyberattack during Zelenskiy’s visit, FT reports

European leaders agree Ukraine security guarantees should include European-led peacekeeping force

UK military chief urges Britain to better prepare for Russia threat

Ukraine says underwater drones hit submarine, but Moscow denies damage

Serbia's prosecutor files to indict minister in connection with Kushner project

French court jails Congo ex-rebel leader for 30 years

Italy's Caltagirone group strengthens governance procedure over Generali, MPS stakes

France says cattle disease under control as farm protests continue

Israeli forces kill Palestinian teen in West Bank, health ministry says

Ukraine could gain NATO-like security assurances in US-proposed Russia peace deal

European drone wall, other 'flagship' defence projects at risk in EU power struggle

Jimmy Lai remains beacon of Hong Kong press freedom, say ex-colleagues awaiting his sentencing

View All Headlines Posts